These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 30185727)

  • 1. [Pharmacological characteristics and clinical efficacies of a novel potassium-competitive acid blocker, vonoprazan fumarate].
    Matsukawa J; Inatomi N; Nishida H; Tsukimi Y
    Nihon Yakurigaku Zasshi; 2018; 152(3):104-110. PubMed ID: 30185727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations.
    Echizen H
    Clin Pharmacokinet; 2016 Apr; 55(4):409-18. PubMed ID: 26369775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potassium-competitive acid blockers: Advanced therapeutic option for acid-related diseases.
    Inatomi N; Matsukawa J; Sakurai Y; Otake K
    Pharmacol Ther; 2016 Dec; 168():12-22. PubMed ID: 27514776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics of the Novel Potassium-Competitive Acid Blocker Vonoprazan Fumarate (TAK-438).
    Otake K; Sakurai Y; Nishida H; Fukui H; Tagawa Y; Yamasaki H; Karashima M; Otsuka K; Inatomi N
    Adv Ther; 2016 Jul; 33(7):1140-57. PubMed ID: 27287852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The binding selectivity of vonoprazan (TAK-438) to the gastric H+, K+ -ATPase.
    Scott DR; Munson KB; Marcus EA; Lambrecht NW; Sachs G
    Aliment Pharmacol Ther; 2015 Dec; 42(11-12):1315-26. PubMed ID: 26423447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Effects of Switching to Vonoprazan, a Novel Potassium-Competitive Acid Blocker, on Gastric Acidity and Reflux Patterns in Patients with Erosive Esophagitis Refractory to Proton Pump Inhibitors.
    Yamashita H; Kanamori A; Kano C; Hashimura H; Matsumoto K; Tsujimae M; Yoshizaki T; Momose K; Obata D; Eguchi T; Fujita M; Okada A
    Digestion; 2017; 96(1):52-59. PubMed ID: 28662503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals.
    Hori Y; Matsukawa J; Takeuchi T; Nishida H; Kajino M; Inatomi N
    J Pharmacol Exp Ther; 2011 Jun; 337(3):797-804. PubMed ID: 21411494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases.
    Hori Y; Imanishi A; Matsukawa J; Tsukimi Y; Nishida H; Arikawa Y; Hirase K; Kajino M; Inatomi N
    J Pharmacol Exp Ther; 2010 Oct; 335(1):231-8. PubMed ID: 20624992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vonoprazan, a Novel Potassium-Competitive Acid Blocker, Should Be Used for the Helicobacter pylori Eradication Therapy as First Choice: A Large Sample Study of Vonoprazan in Real World Compared with Our Randomized Control Trial Using Second-Generation Proton Pump Inhibitors for Helicobacter pylori Eradication Therapy.
    Ozaki H; Harada S; Takeuchi T; Kawaguchi S; Takahashi Y; Kojima Y; Ota K; Hongo Y; Ashida K; Sakaguchi M; Tokioka S; Sakamoto H; Furuta T; Tominaga K; Higuchi K
    Digestion; 2018; 97(3):212-218. PubMed ID: 29393194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vonoprazan fumarate for the management of acid-related diseases.
    Martinucci I; Blandizzi C; Bodini G; Marabotto E; Savarino V; Marchi S; de Bortoli N; Savarino E
    Expert Opin Pharmacother; 2017 Aug; 18(11):1145-1152. PubMed ID: 28657473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vonoprazan: A Novel and Potent Alternative in the Treatment of Acid-Related Diseases.
    Yang X; Li Y; Sun Y; Zhang M; Guo C; Mirza IA; Li YQ
    Dig Dis Sci; 2018 Feb; 63(2):302-311. PubMed ID: 29282636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of Acid-related Diseases Using Potassium-competitive Acid Blockers].
    Choi YJ
    Korean J Gastroenterol; 2022 Dec; 80(6):247-253. PubMed ID: 36567437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of effect of an increased dosage of vonoprazan versus vonoprazan plus lafutidine on gastric acid inhibition and serum gastrin.
    Suzuki T; Kagami T; Uotani T; Yamade M; Hamaya Y; Iwaizumi M; Osawa S; Sugimoto K; Miyajima H; Furuta T
    Eur J Clin Pharmacol; 2018 Jan; 74(1):45-52. PubMed ID: 28986609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KFP-H008 blocks gastric acid secretion through inhibiting H
    Li CY; Su M; Yan YY; Zhou L; Ao LY; Fang WR; Li YM
    Eur J Pharmacol; 2017 Sep; 810():112-119. PubMed ID: 28629736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype.
    Kagami T; Sahara S; Ichikawa H; Uotani T; Yamade M; Sugimoto M; Hamaya Y; Iwaizumi M; Osawa S; Sugimoto K; Miyajima H; Furuta T
    Aliment Pharmacol Ther; 2016 May; 43(10):1048-59. PubMed ID: 26991399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiographic Localization Study of a Novel Potassium-Competitive Acid Blocker, Vonoprazan, in the Rat Gastric Mucosa.
    Matsukawa J; Kogame A; Tagawa Y; Inatomi N
    Dig Dis Sci; 2016 Jul; 61(7):1888-94. PubMed ID: 26961787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-throughput screening of potassium-competitive acid blockers.
    Kondo M; Kawamoto M; Hasuoka A; Kajino M; Inatomi N; Tarui N
    J Biomol Screen; 2012 Feb; 17(2):177-82. PubMed ID: 21940711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative study: Vonoprazan and proton pump inhibitors in
    Sakurai K; Suda H; Ido Y; Takeichi T; Okuda A; Hasuda K; Hattori M
    World J Gastroenterol; 2017 Jan; 23(4):668-675. PubMed ID: 28216974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamics and Pharmacokinetics of the Potassium-Competitive Acid Blocker Vonoprazan and the Proton Pump Inhibitor Lansoprazole in US Subjects.
    Laine L; Sharma P; Mulford DJ; Hunt B; Leifke E; Smith N; Howden CW
    Am J Gastroenterol; 2022 Jul; 117(7):1158-1161. PubMed ID: 35294415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study.
    Murakami K; Sakurai Y; Shiino M; Funao N; Nishimura A; Asaka M
    Gut; 2016 Sep; 65(9):1439-46. PubMed ID: 26935876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.